Biocon Pharma receives Health Canada approval for micafungin injection. The pharmaceutical company's arm has secured regulatory clearance for the antifungal treatment in 50 mg and 100 mg strengths. The approved product treats candidemia, acute disseminated candidiasis, candida peritonitis, abscesses, and esophageal candidiasis in adults and children four months and older. Additionally, it provides prophylaxis for Candida infections in patients undergoing hematopoietic stem cell transplantation. This approval strengthens Biocon's integrated biosimilars and generics portfolio, expanding its presence in the Canadian pharmaceutical market and supporting growth in its specialty pharmaceutical segment.
Post from MarketNews_en
Log in to interact with content.